AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.01 USD
-1.41 (-3.32%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $40.94 -0.07 (-0.17%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth F Momentum B VGM
Zacks News
Zacks.com featured highlights include: AMN, Kemper, United Airlines and UniFirst
by Zacks Equity Research
Zacks.com featured highlights include: AMN, Kemper, United Airlines and UniFirst
Why AMN Healthcare (AMN) Could Beat Earnings Estimates Again
by Zacks Equity Research
AMN Healthcare (AMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
4 Stocks With Relative Price Strength to Enhance Your Gains
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
AMN vs. HQY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. HQY: Which Stock Is the Better Value Option?
All You Need to Know About AMN Healthcare (AMN) Rating Upgrade to Strong Buy
by Zacks Equity Research
AMN Healthcare (AMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for July 3rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
AMN Healthcare (AMN) Closes Advanced Medical Acquisition
by Zacks Equity Research
AMN Healthcare (AMN) completes Advanced Medical buyout that will help the former to boost offerings in some of the fastest growing and very important care settings.
Why Is AMN Healthcare (AMN) Down 4.6% Since Last Earnings Report?
by Zacks Equity Research
AMN Healthcare (AMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AMN Healthcare (AMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Higher revenues and expansion in gross margin find reflection in AMN Healthcare's (AMN) Q1 results. However, weak performance at Nurse and Allied and Locum Tenens segments remain woes.
AMN Healthcare Services (AMN) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 8.70% and 1.45%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AMN Healthcare Services (AMN) Q1 Earnings Expected to Decline
by Zacks Equity Research
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMN Healthcare Down on Soft Locum Tenens Business, Dull View
by Zacks Equity Research
Dependence on third parties is detrimental for AMN Healthcare (AMN).
AMN Healthcare (AMN) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) Q4 results get a boost from Nurse and Allied Solutions and Other Workforce Solutions segments.
New Strong Sell Stocks for March 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
AMN Healthcare Services (AMN) Q4 Earnings Top Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 1.25% and -1.97%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
AMN Healthcare Services (AMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Teladoc in 2019, After a Strong 2018?
by Zacks Equity Research
Teladoc (TDOC) should continue to gain from increasing demand for its services and global expansion.
Cigna Poised for Growth in 2019 on Express Scripts Buyout
by Zacks Equity Research
The purchase of Express Scripts by Cigna (CI) has diversified its business, which should fuel long-term growth.
AMN or ICLR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. ICLR: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: Verint Systems, Integer, AMN Healthcare Services, Xilinx and United States Cellular
by Zacks Equity Research
Zacks.com featured highlights include: Verint Systems, Integer, AMN Healthcare Services, Xilinx and United States Cellular
5 Stocks Trading Near 52-Week High with More Room to Run
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
Teladoc (TDOC) Surges 64% in a Year: Can the Rally Continue?
by Zacks Equity Research
Teladoc (TDOC) is poised to grow on accelerating demand for its telehealth services.
Express Scripts (ESRX) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Express Scripts (ESRX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AMN vs. ICLR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMN vs. ICLR: Which Stock Is the Better Value Option?